A Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccination

Chen, Guan-JhouGuan-JhouChenHSIN-YUN SUNKUAN-YIN LINSZU-MIN HSIEHYU-CHUNG CHUANGWANG-DA LIUYU-SHAN HUANGSUNG-CHING PANUN-IN WUARISTINE CHENGYI-CHIA HUANGWu, Cheng-HsinCheng-HsinWuSu, Yi-ChingYi-ChingSuLiu, Wen-ChunWen-ChunLiuSUI-YUAN CHANGCHIEN-CHING HUNG2023-09-072023-09-072023-08-221058-48381537-6591https://scholars.lib.ntu.edu.tw/handle/123456789/635184For people with human immunodeficiency virus (PWH) who have no serological responses to their primary hepatitis A virus (HAV) vaccination or have seroreversion after successful primary vaccination, the optimal revaccination strategy remains unclear.enfecal–oral transmission; immunization; men who have sex with men; outbreak; viral hepatitisA Randomized Clinical Trial of 1-Dose vs Accelerated 2-Dose Schedule for Hepatitis A Virus (HAV) Revaccination Among People With Human Immunodeficiency Virus Who Were Nonresponders or Had Seroreversion After Primary HAV Vaccinationjournal article10.1093/cid/ciad206370364042-s2.0-85166578295https://api.elsevier.com/content/abstract/scopus_id/85166578295